Rapid, seamless generation of recombinant poxviruses using host-range and visual selection
Abstract
Vaccinia virus (VACV) was instrumental in eradicating variola virus (VARV), the causative agent of smallpox, from nature. Since this first use as a vaccine, VACV has been developed as a vector for therapeutic vaccines and as an oncolytic virus. These applications take advantage of VACVs easily manipulated genetics and broad host range as an outstanding platform to generate recombinant therapeutics. Several methods have been developed to generate recombinant VACV, including marker selection methods and transient dominant selection. Here, we present a refinement of a host-range selection method coupled with visual identification. Our method takes advantage of selective pressure generated by the host antiviral protein kinase R (PKR) coupled with a fluorescent fusion gene expressing mCherry-tagged E3L, one of two VACV PKR antagonists. This method permits rapid, seamless generation of rVACV in a variety of cell types.
02 /Specification & Classification
Click any tag to browse matching papers- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Bi-reporter vaccinia virus for tracking viral infections in vitro and in vivo
K. Chiem, M. Lorenzo, … L. Martinez-Sobrido·Microbiology SpectrumPeer-reviewed·Dec 22, 2021
- MAVERICC: Efficient marker-free rescue of vaccinia virus recombinants by in vitro CRISPR-Cas9 engineering
E. Laudermilch, K. Chandran·bioRxiv·Jan 5, 2021
- Accelerated selection of a viral RNA polymerase variant during gene copy number amplification promotes rapid evolution of vaccinia virus
Kelsey R. Cone, Zev N. Kronenberg, … Nels C. Elde·Journal of VirologyPeer-reviewed·Feb 15, 2017
- Antiviral activities of two nucleos(t)ide analogs against vaccinia and mpox viruses in primary human fibroblasts
- Synthetic Genome Shuffling of Poxviruses through Yeast for Next-Generation Oncolytic Platforms
Aimeric Agaoua, C. Rey, … Philippe Erbs·bioRxiv·Mar 6, 2026
- Antivirals against monkeypox infections
K. Chiem, A. Nogales, … L. Martinez-Sobrido·bioRxiv·Apr 19, 2023